Clover Health Investments, Corp. (CLOV)
Clover Health: Strong Growth, Improving Margins, And A Mispriced Stock
Clover Health is positioned for a major turnaround, with operations and profitability metrics improving sharply despite market skepticism. CLOV projects 46% membership growth and 49% revenue growth for 2026, guiding toward its first full year of positive GAAP net income. Operating leverage is materializing as SG&A improves, member retention exceeds 95%, and mature cohorts deliver over $200 monthly profit per member.
Here's Why You Should Retain Clover Stock in Your Portfolio for Now
CLOV rides 38% Medicare Advantage growth and rising EBITDA, but higher medical costs and policy risks cloud its near-term margin outlook.
Clover Health Q4 Earnings Meet Estimates, Sales Beat, Membership Rises
CLOV Q4 loss matches estimates. Revenues jump 45%.
Clover Health Investments, Corp. (CLOV) Q4 2025 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Q4 2025 Earnings Call Transcript
Clover Health Is Undervalued With Clear Signs Of A 2026 Profit Breakout
Clover Health Investments is now a contrarian buy, with the market underestimating its path to profitability in 2026. CLOV's member retention exceeds 90%, older cohorts generate $217 monthly profit, and the Clover Assistant AI is driving clinical and financial improvements. The stock trades at less than 0.5x 2026 sales, with a fair value estimate of $3.30 per share—28% above current levels.
Here's Why You Should Retain CLOV Stock in Your Portfolio for Now
Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.
Clover Health Investments, Corp. (CLOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Clover Health Investments, Corp. (CLOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CLOV Reports MA Membership Growth, Signals GAAP Profitability in 2026
Clover Health posts 53% AEP PPO membership growth, lifts total members to 153,000, and says the momentum positions it for GAAP net income profitability in 2026.
Here's Why You Should Retain CLOV Stock in Your Portfolio Now
Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.
Clover Health Investments, Corp. (CLOV) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Clover Health Investments, Corp. (CLOV) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Why Is Clover Health Investments (CLOV) Down 11.6% Since Last Earnings Report?
Clover Health Investments (CLOV) reported earnings 30 days ago. What's next for the stock?
Clover Health: Smart Money Should Be Accumulating Ahead Of 2026 GAAP Profits
Despite disappointing YTD earnings due to higher than expected medical costs, Clover's expected GAAP profitability in 2026 marks a critical inflection point. Clover's higher returning member mix and targeted growth measures aiming to bring more members under Clover Assistant quicker are major tailwinds to medical costs next year, in my opinion. Clover Assistant's early diagnosis capabilities set the company up to benefit from the CMS' Part D measures aiming to normalize cost pressures on plans, in my opinion.
